Condition: Recipients of Allogeneic Stem Cell Transplantation · HPV (Human Papillomavirus)-Associated · Acute Myeloid Leukaemia · Sponsor: Vastra Gotaland Region
Patients who undergo allogeneic stem cell transplantation lose previously acquired immunity and are routinely revaccinated against many infectious diseases. For several reasons, these patients have a long-term immune deficiency due to the transplant itself (lack of immune reconstitution) and due to possible complications, primarily GvHD and its treatment. The risk of secondary malignancy in the long-term following an allogeneic bone marrow transplant is greatly increased, and secondary cancer cases account for a significant proportion of late deaths in both women and men after transplantation. Some of these secondary cancers are associated with HPV. The risk of cervical cancer has been reported to be 13 times increased compared to a healthy population. Therefore in this trial, the aim is to study immune response (antigen-specific antibody response) after vaccination with 9-valent HPV vaccine (Gardasil 9®) in adult women and men (up to and including 45 years of age) who have undergone allogeneic stem cell transplantation. In this trial, the sponsor will compare "early" (start 9 months after tx) with "late" (start 15 months after tx) vaccination.
This description comes directly from the study's public registry record.
Sigrun Einarsdottir, MD, PhD · 0046313427358 · sigrun.einarsdottir@vgregion.se
Always discuss trial participation with your own doctor first.
| Skåne's University Hospital | Lund, Region Skåne, Sweden | Not Yet Recruiting |
| Karolinska University Hospital | Stockholm, Region Stockholm, Sweden | Not Yet Recruiting |
| Uppsala University Hospital | Uppsala, Region Uppsala, Sweden | Recruiting |
| Linköping University Hospital | Linköping, Region Östergötaland, Sweden | Recruiting |
| Sahlgrenska University Hospital | Gothenburg, Västra Götalands Region, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06793410